Michael J. DeVit

4.2k total citations · 2 hit papers
19 papers, 2.8k citations indexed

About

Michael J. DeVit is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Michael J. DeVit has authored 19 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Michael J. DeVit's work include Monoclonal and Polyclonal Antibodies Research (10 papers), HER2/EGFR in Cancer Research (9 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Michael J. DeVit is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), HER2/EGFR in Cancer Research (9 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Michael J. DeVit collaborates with scholars based in United States. Michael J. DeVit's co-authors include Stephen Albert Johnston, De‐chu C. Tang, Mark Johnston, Stephen B. Willingham, Tiago F. Outeiro, Susan Lindquist, Paul J. Muchowski, R. Sanders Williams, S. A. Johnston and John C. Sanford and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael J. DeVit

19 papers receiving 2.7k citations

Hit Papers

Genetic immunization is a simple method for eliciting an ... 1992 2026 2003 2014 1992 2012 250 500 750 1000

Peers

Michael J. DeVit
Michael J. DeVit
Citations per year, relative to Michael J. DeVit Michael J. DeVit (= 1×) peers Yasuhiko Horiguchi

Countries citing papers authored by Michael J. DeVit

Since Specialization
Citations

This map shows the geographic impact of Michael J. DeVit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. DeVit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. DeVit more than expected).

Fields of papers citing papers by Michael J. DeVit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. DeVit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. DeVit. The network helps show where Michael J. DeVit may publish in the future.

Co-authorship network of co-authors of Michael J. DeVit

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. DeVit. A scholar is included among the top collaborators of Michael J. DeVit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. DeVit. Michael J. DeVit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Gumerov, Dmitry R., Elena Ter‐Ovanesyan, Patrick R. Conlon, et al.. (2017). Abstract 48: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate. Cancer Research. 77(13_Supplement). 48–48. 11 indexed citations
2.
Gumerov, Dmitry R., Dongmei Xiao, Joshua D. Thomas, et al.. (2016). Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC). Cancer Research. 76(14_Supplement). 596–596. 2 indexed citations
4.
Bodyak, Natalya D., Michael J. DeVit, Mao Yin, et al.. (2016). Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer. Cancer Research. 76(4_Supplement). P4–14. 13 indexed citations
5.
Bergstrom, Donald A., Natalya D. Bodyak, Peter U. Park, et al.. (2015). Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors. Cancer Research. 75(15_Supplement). LB–231. 12 indexed citations
6.
Bodyak, Natalya D., Peter U. Park, Dmitry R. Gumerov, et al.. (2015). Abstract 641: Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species. Cancer Research. 75(15_Supplement). 641–641. 6 indexed citations
7.
Bodyak, Natalya D., Mao Yin, Joshua D. Thomas, et al.. (2014). Abstract 2645: Advantages of polyacetal polymer-based ADCs: Application to low expression targets. Cancer Research. 74(19_Supplement). 2645–2645. 1 indexed citations
9.
Bodyak, Natalya D., Mao Yin, Joshua D. Thomas, et al.. (2013). Abstract 4331: Advantages of polyacetal polymer-based antibody drug conjugates employing cysteine bioconjugation.. Cancer Research. 73(8_Supplement). 4331–4331. 2 indexed citations
10.
Bulawa, Christine, Stephen Connelly, Michael J. DeVit, et al.. (2012). Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences. 109(24). 9629–9634. 572 indexed citations breakdown →
11.
DeVit, Michael J., et al.. (2005). Forcing interactions as a genetic screen to identify proteins that exert a defined activity. Genome Research. 15(4). 560–565. 6 indexed citations
12.
Willingham, Stephen B., Tiago F. Outeiro, Michael J. DeVit, Susan Lindquist, & Paul J. Muchowski. (2003). Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein. Science. 302(5651). 1769–1772. 328 indexed citations
13.
Johnston, Stephen Albert & Michael J. DeVit. (2003). Biolistic Transformation of Yeasts. Humana Press eBooks. 53. 147–154. 5 indexed citations
14.
DeVit, Michael J. & Mark Johnston. (1999). The nuclear exportin Msn5 is required for nuclear export of the Mig1 glucose repressor of Saccharomyces cerevisiae. Current Biology. 9(21). 1231–1241. 167 indexed citations
15.
Iyer, Vishwanath R., et al.. (1998). Characterization of Three Related Glucose Repressors and Genes They Regulate in Saccharomyces cerevisiae. Genetics. 150(4). 1377–1391. 151 indexed citations
16.
Tang, De‐chu C., Michael J. DeVit, & Stephen Albert Johnston. (1992). Genetic immunization is a simple method for eliciting an immune response. Nature. 356(6365). 152–154. 1199 indexed citations breakdown →
17.
Griffin, David H., M. Schaedle, Michael J. DeVit, & Paul D. Manion. (1991). Clonal variation of Populus tremuloides responses to diurnal drought stress. Tree Physiology. 8(3). 297–304. 16 indexed citations
18.
Williams, R. Sanders, et al.. (1991). Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles.. Proceedings of the National Academy of Sciences. 88(7). 2726–2730. 323 indexed citations
19.
Griffin, David H., M. Schaedle, Paul D. Manion, & Michael J. DeVit. (1991). Clonal variation in amino acid contents of roots, stems, and leaves of aspen (Populus tremuloides Michx.) as influenced by diurnal drought stress. Tree Physiology. 8(4). 337–350. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026